Ovarian Cancer

Incomplete pregnancies appeared associated with reduced risk for invasive epithelial ovarian cancer, according to results of a study published in Journal of the National Cancer Institute.

Nivolumab did not improve overall survival compared with gemcitabine or pegylated liposomal doxorubicin in platinum-resistant ovarian cancer; however, it was better tolerated, according to results presented at ESMO Virtual Congress 2020.

KELIM, a model-based parameter from CA-125 kinetics, was an independent prognostic factor of progression-free survival for 5 years after first-line treatment in patients with ovarian cancer, according to data presented at ESMO Virtual Congress 2020.

Triple therapy with olaparib plus durvalumab and bevacizumab were well-tolerated in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer, according to data presented at ESMO Virtual Congress 2020.

Adding maintenance olaparib to bevacizumab provided a benefit beyond first progression, with a substantial second progression-free survival benefit, in patients with newly diagnosed, advanced high-grade ovarian carcinoma, according to data presented at ESMO Virtual Congress 2020.

Patients with gynecologic cancers that responded to first-line platinum-based chemotherapy receiving niraparib did not show lower health-related quality of life compared with placebo, according to data presented at ESMO Virtual Congress 2020.

Veliparib plus carboplatin/paclitaxel followed by veliparib maintenance showed smaller improvements in health-related quality of life measures from baseline compared with carboplatin/paclitaxel alone among patients with newly diagnosed stage III or IV ovarian cancer.

Subsequent chemotherapy showed less efficacy in BRCA 1 and 2-mutated, platinum-sensitive, recurrent epithelial ovarian cancer treated with maintenance olaparib compared with placebo, according to a presentation at ESMO Virtual Congress 2020.

Adding pazopanib to paclitaxel in patients with recurrent ovarian cancer progressing during bevacizumab maintenance therapy was not superior to paclitaxel alone, according to data presented at ESMO Virtual Congress 2020.

September is Gynecologic Cancer Awareness Month, an awareness campaign launched in 1999 by Foundation for Women’s Cancer.